Clinical Trials on Regulatory B Cells in United Kingdom

Total 17865 results

University Hospital Southampton NHS Foundation...
Hoffmann-La Roche

Terminated

Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy (ARGO)

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United Kingdom
Royal Marsden NHS Foundation Trust
Hoffmann-La Roche

Terminated

R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma

B-cell Lymphoma | Non-Hodgkin's Lymphoma

United Kingdom
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC; Mundipharma-EDO GmbH

Withdrawn

A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL

Relapsed or Refractory Diffuse Large B-cell Lymphoma

United Kingdom
University College, London

Completed

Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation (COBALT)

Diffuse Large B-Cell Lymphoma

United Kingdom
Royal Marsden NHS Foundation Trust
Celgene Corporation

Active, not recruiting

Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND) (LEGEND)

Diffuse Large B-Cell Lymphoma

United Kingdom
University of Southampton
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (P+R-ICE)

Diffuse Large B Cell Lymphoma

United Kingdom
Hoffmann-La Roche

Completed

Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma

United Kingdom
University College, London
Novartis Pharmaceuticals

Active, not recruiting

RadiothErapy priMIng for CAR-T (REMIT)

Diffuse Large B Cell Lymphoma

United Kingdom
University College London Hospitals

Completed

CAR T Cell Therapy Related Cardiovascular Outcomes (CARTCO)

Cardiovascular Diseases | Diffuse Large B Cell Lymphoma | Cardiotoxicity | B-cell Acute Lymphoblastic Leukemia | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | B-cell Lymphoma Refractory | Cardiovascular Complication | B-cell Lymphoma Recurrent

United Kingdom
Oxford University Hospitals NHS Trust
University of Manchester; The Christie NHS Foundation Trust; Early Phase Cancer...

Completed

AZD1152 in Diffuse Large B-cell Lymphoma

Lymphoma

United Kingdom
Cambridge University Hospitals NHS Foundation Trust
AstraZeneca; Cancer Research UK Cambridge Institute

Recruiting

DLBCL Interim Response Evaluation for Customised Therapy (DIRECT)

High-grade B-cell Lymphoma

United Kingdom
University College, London

Completed

Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Lymphoma

United Kingdom
GlaxoSmithKline

Completed

Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant

Lymphoma, Large-Cell, Diffuse

United Kingdom
Epizyme, Inc.

Completed

Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors

Follicular Lymphoma | Marginal Zone Lymphoma | Advanced Solid Tumors | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal Lymphoma

United Kingdom
Acrotech Biopharma Inc.

Completed

Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma

United Kingdom, United States
NovalGen Ltd.

Recruiting

First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Non-small Cell Lung Cancer (NSCLC) | Small Lymphocytic Lymphoma | Malignant Melanoma | Chronic Lymphocytic Leukaemia

United Kingdom
Onxeo

Completed

A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL

B-cell Chronic Lymphocytic Leukemia

United Kingdom
University Hospital Southampton NHS Foundation...

Completed

A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL) (ACCEPT)

Non Hodgkin Lymphoma

United Kingdom
Cancer Research UK

Withdrawn

Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

Lymphoma

United Kingdom
University College, London

Recruiting

Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 (ALLCAR19)

Leukemia, Lymphoblastic, Acute, Lymphoma

United Kingdom
University Hospital Southampton NHS Foundation...
Cancer Research UK; The Christie NHS Foundation Trust; Celldex Therapeutics; Oxford... and other collaborators

Active, not recruiting

A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma (RiVa)

B Cell Lymphoma

United Kingdom
Acerta Pharma BV

Active, not recruiting

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)

United States, United Kingdom
Autolus Limited

Recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

United Kingdom
University of Birmingham
AstraZeneca; Cancer Research UK; Bloodwise

Completed

An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (TORCH)

Diffuse Large B-Cell Lymphoma

United Kingdom
Nordic Nanovector

Completed

Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

Refractory Diffuse Large B-Cell Lymphoma | Relapsed, Diffuse Large B-cell Lymphoma

Spain, United Kingdom, Italy, United States, Germany
Autolus Limited

Completed

CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER)

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell Lymphoma

United States, United Kingdom
Cancer Research UK
BioInvent International AB; Bloodwise

Completed

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

B-cell Lymphoma | Waldenström Macroglobulinemia | Chronic Lymphocytic Leukaemia

United Kingdom
Cancer Research UK

Completed

A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies

Chronic Lymphocytic Leukaemia | Indolent B-cell Lymphoma | Waldenström Macroglobulinaemia

United Kingdom
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Unknown

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

B-cell Non Hodgkin Lymphoma | Mature B-cell Leukemia Burkitt-type

Belgium, France, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain, China
University of Kentucky
American College of Allergy, Asthma and Immunology

Withdrawn

Oral Contraceptives and Asthma Control

Asthma | Regulatory T Cell Function

United States
Memorial Sloan Kettering Cancer Center
Sobi, Inc.

Recruiting

A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

Immune System Diseases | Autoimmune Lymphoproliferative | Primary Immune Regulatory Disorder

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin UK, Ltd.

Completed

A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma

Multiple Myeloma | Chronic Lymphocytic Leukaemia | B-cell Non-Hodgkin's Lymphoma

United Kingdom
Kymera Therapeutics, Inc.

Suspended

Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients With Relapsed or Refractory B-cell NHL

Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | DLBCL | MYD88 Gene Mutation

United States, United Kingdom
Gilead Sciences

Completed

Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-cell Malignancies

France, United Kingdom
Cancer Research UK
AstraZeneca

Completed

A Phase I Trial of AZD3965 in Patients With Advanced Cancer

Adult Solid Tumor | Burkitt Lymphoma | Diffuse Large B Cell Lymphoma

United Kingdom
Regeneron Pharmaceuticals

Completed

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (ORCHID)

Diffuse Large B-Cell Lymphoma

Austria, France, Germany, United Kingdom
Telios Pharma, Inc.

Active, not recruiting

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Relapsed/Refractory B Cell Malignancies | Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma | Treatment-Naive B Cell Malignancies

United States, Poland, Ukraine, Hungary, Italy, Russian Federation, United Kingdom
University College, London

Completed

Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) (LenD)

Chronic Lymphocytic Leukemia

United Kingdom
King's College Hospital NHS Trust

Completed

CLL Empirical Antibiotic Regimen (CLEAR)

Chronic Lymphocytic Leukaemia (CLL)

United Kingdom
Royal Marsden NHS Foundation Trust
Cambridge University Hospitals NHS Foundation Trust; University Hospital Plymouth...

Unknown

Tissue Collection for Biomarkers Determining Resistance to Ibrutinib (CLARITY)

Mantle Cell Lymphoma | Chronic Lymphocytic Leukaemia

United Kingdom
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Treatment of Mature B-cell Lymphoma/Leukaemia

B-Cell Lymphoma

France, United Kingdom, United States
Lymphoma Study Association

Completed

R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

Lymphoma, Large-Cell, Diffuse

United States, Australia, Belgium, Czechia, Finland, Germany, Israel, Sweden, Switzerland, United Kingdom
Gilead Sciences

Active, not recruiting

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

B-cell Malignancies

United States, United Kingdom, France
Royal Marsden NHS Foundation Trust

Unknown

Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0 (BMPB)

Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL)

United Kingdom
The Royal Bournemouth Hospital
CLL Topics, Inc.

Terminated

Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients (CLLIFVAC)

Chronic Lymphocytic Leukemia

United Kingdom
Cancer Research UK
Aleta BioTherapeutics

Recruiting

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell

United Kingdom
Acerta Pharma BV
AstraZeneca

Completed

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) (PRISM)

Diffuse Large B Cell Lymphoma | NHL | Non-hodgkin's Lymphoma | DLBCL

United States, United Kingdom
University of Surrey
American Society of Hematology

Recruiting

Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia (HIT-CLL)

Frailty | Chronic Lymphocytic Leukemia | Muscle Function | Immune Function | Lipid Cell; Tumor

United Kingdom
MedImmune LLC

Completed

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Diffuse Large B-Cell Lymphoma

United States, France, United Kingdom, Ireland
Kite, A Gilead Company

Recruiting

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Relapsed and/or Refractory B-cell Lymphoma

United States, Netherlands, United Kingdom, Germany

Clinical Trials on Regulatory B Cells in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations